ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tenofovir alafenamide

Also written as “E/C/F/TAF”, “TAF” and “B/F/TAF”.

Its studies are mostly in Acquired Immunodeficiency Syndrome · Hepatitis B, Chronic · HIV Infections · Hepatitis · Coinfection, led by 7 companies.

Drug pageTenofovir alafenamide: every studyMany companies study it; this page follows only the 61 they lead. All 140 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 23, 202361 company-led studies, 10 open or runningNext primary completion: Jun 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences499 open or runningphase 4since Oct 23, 2023May 13, 2002Jun 2027phase 4 · NCT06337032
Johnson & Johnsonits history only70 open or runningphase 3since Oct 17, 2014Oct 17, 2014none ahead
Henan Genuine Biotechits history only10 open or runningphase 1since May 13, 2025May 13, 2025none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Sep 9, 2024Sep 9, 2024none ahead
New Discoveryits history only10 open or runningphase 4since Dec 6, 2019Dec 6, 2019none ahead
The Crofoot Research Centerits history only10 open or runningphase 4since May 12, 2020May 12, 2020none ahead
Xiamen Amoytop Biotechits history only11 open or runningno phasesince Nov 24, 2024Nov 24, 2024May 31, 2029NCT06707922

Also a collaborator on its studies: Merck and F-star Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Gilead Sciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 35 studies since May 13, 2002.

  1. Jan 12, 2018Phase 3 study in HIV-1 InfectionNCT03405935 · 86 enrolled · Belgium, France, Italy and more
  2. Feb 9, 2018Phase 2 study in Hepatitis B, ChronicNCT03434353 · 123 enrolled · Hong Kong, Korea, Republic of
  3. May 24, 2018Phase 3 study in HIV-1/HBV Co-InfectionNCT03547908 · 244 enrolled · United States, China, Dominican Republic and more
  4. Aug 13, 2018Phase 3 study in HIV-1 InfectionNCT03631732 · 496 enrolled · United States
  5. Nov 2, 2018Phase 1 study in HIV-1 InfectionNCT03739866 · 53 enrolled · United States
  6. May 21, 2019Phase 1 study in HIV-1-infectionNCT03960645 · 62 enrolled · United States, Dominican Republic, Thailand
  7. Oct 28, 2019Phase 2 study in HIV-1-infectionNCT04143594 · 183 enrolled · United States, Dominican Republic, Puerto Rico
  8. Aug 2, 2021Phase 3 study in Pre-Exposure Prophylaxis of HIV InfectionNCT04994509 · 5,368 enrolled · South Africa, Uganda
  9. Oct 23, 2023Phase 4 study in HIV-1-infectionNCT06104306 · 33 enrolled · United States, Canada, France
  10. Mar 22, 2024Phase 4 study in HIV-1-infectionNCT06337032 · 350 planned · Argentina, Panama, South Africa and more
  11. Oct 4, 2024Phase 3 study in HIV-1-infectionNCT06630286 · 609 enrolled · United States, Argentina, Australia and more
  12. Jun 27, 2025Phase 1 study in HIV-1-infectionNCT07055451 · 16 enrolled · United States, South Africa
  13. Jun 8, 2026Phase 2 study in HIV-1-infectionNCT07645287 · 175 planned · United States, Australia, Canada and more
  14. Jul 13, 2026Phase 3 study in HIV-1-infectionNCT07708727 · 700 planned · United States, Canada, Germany and more

Ahead

  1. Jun 2027Primary completion: phase 4 study in HIV-1-infectionNCT06337032
  2. Aug 2027Primary completion: phase 2 study in HIV-1-infectionNCT07645287
  3. Mar 2028Primary completion: phase 1 study in HIV-1-infectionNCT07055451
  4. Oct 2030Primary completion: phase 3 study in HIV-1-infectionNCT07708727

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human immunodeficiency virus type 1 reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule

Studies

All 49 Gilead Sciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07708727HIV-1-infection · United States, Canada, Germany and more3RecruitingOct 2030700
NCT07645287HIV-1-infection · United States, Australia, Canada and more2RecruitingAug 2027175
NCT07055451HIV-1-infection · United States, South Africa1Active, not recruitingMar 202816
NCT06630286HIV-1-infection · United States, Argentina, Australia and more3Active, not recruitingApr 17, 2026609
NCT06337032HIV-1-infection · Argentina, Panama, South Africa and more4RecruitingJun 2027350
NCT06104306HIV-1-infection · United States, Canada, France4CompletedJan 29, 202533
NCT04994509Pre-Exposure Prophylaxis of HIV Infection · South Africa, Uganda3Active, not recruitingMay 27, 20245,368
NCT04143594HIV-1-infection · United States, Dominican Republic, Puerto Rico2CompletedOct 5, 2021183
NCT03960645HIV-1-infection · United States, Dominican Republic, Thailand1CompletedJul 21, 202262
NCT03739866HIV-1 Infection · United States1CompletedNov 14, 201953
NCT03631732HIV-1 Infection · United States3CompletedAug 12, 2019496
NCT03547908HIV-1/HBV Co-Infection · United States, China, Dominican Republic and more3CompletedFeb 25, 2022244
NCT03434353Hepatitis B, Chronic · Hong Kong, Korea, Republic of2TerminatedJan 20, 2020123
NCT03405935HIV-1 Infection · Belgium, France, Italy and more3CompletedNov 20, 201886
NCT03180619Hepatitis B, Chronic · United States, Canada, Hong Kong and more2CompletedMar 27, 2019124
NCT03110380HIV-1-infection · United States, Austria, Canada and more3CompletedDec 4, 2018567
NCT02932150Hepatitis B, Chronic · United States, Belgium, Hong Kong and more2Active, not recruitingOct 27, 2026150
NCT02881320HIV-1 Infection · United States, South Africa, Thailand and more3Active, not recruitingMar 24, 2025177
NCT02862548Hepatitis B, Chronic · New Zealand2CompletedFeb 8, 201851
NCT02842086Pre-Exposure Prophylaxis of HIV-1 Infection · United States, Austria, Canada and more3TerminatedJan 31, 20195,399
NCT02836249Hepatitis · China3CompletedMar 21, 2017181
NCT02836236Hepatitis · China3CompletedApr 5, 2017155
NCT02707601Hepatitis C · United States, Puerto Rico3CompletedSep 14, 2017150
NCT02652624HIV-1 Infection · United States, Dominican Republic, Puerto Rico and more3CompletedOct 9, 2017472
NCT02616029HIV-1 Infection · United States, France, Germany and more3CompletedOct 11, 201866
NCT02616783HIV-1 Infection · Belgium, France, Italy and more3CompletedFeb 21, 2018167
NCT02605954HIV-1 Infection · United States, France, Germany and more3CompletedJun 14, 2017275
NCT02607956HIV-1 Infection · United States, Australia, Belgium and more3CompletedMay 12, 2017657
NCT02600819Kidney Failure, Chronic · United States, Austria, France and more3CompletedSep 29, 201755
NCT02469246HIV-1 Infection · United States, Belgium, Canada and more3CompletedDec 11, 2017567
NCT02397694HIV-1 Infection · United States2CompletedNov 30, 201598
NCT02296853Hepatitis B · United States, Germany, New Zealand1CompletedApr 17, 201520
NCT02276612HIV · United States, South Africa3CompletedNov 10, 201660
NCT02121795HIV-1 Infection · United States, Belgium, Canada and more3CompletedAug 12, 2015668
NCT02071082Coinfection · United States, Canada, Japan3CompletedJan 23, 201579
NCT02016924Acquired Immunodeficiency Syndrome · United States, Argentina, South Africa and more3Active, not recruitingJun 13, 2025133
NCT01967940HIV Infections · United States, Dominican Republic, Russian Federation and more3CompletedMay 21, 201555
NCT01968551HIV Infections · United States, Canada3CompletedJul 21, 2015158
NCT01940471Hepatitis · United States, Australia, Bulgaria and more3CompletedNov 16, 2015875
NCT01940341Hepatitis · United States, Australia, Canada and more3CompletedSep 30, 2015426
NCT01854775Acquired Immunodeficiency Syndrome · United States, South Africa, Thailand and more3CompletedMay 11, 2020129
NCT01818596HIV Infections · United States, Australia, Dominican Republic and more3CompletedJul 31, 2014252
NCT01815736HIV Infections · United States, Australia, Austria and more3CompletedMar 16, 20151,443
NCT01797445HIV Infections · United States, Canada, Dominican Republic and more3CompletedSep 19, 2014872
NCT01780506HIV Infections · United States, Australia, Austria and more3CompletedAug 26, 2014872
NCT01671787Hepatitis B, Chronic · United States, Australia, Canada and more1CompletedApr 201351
NCT01565850Acquired Immunodeficiency Syndrome · United States, Puerto Rico2CompletedJan 2013153
NCT01497899Acquired Immunodeficiency Syndrome · United States, Puerto Rico2CompletedOct 17, 2012279
NCT00036634HIV Infections · United States2CompletedFeb 200330

How it is read

Names in the registry

  • “E/C/F/TAF”, 17 entries
  • “TAF”, 12 entries
  • “B/F/TAF”, 10 entries
  • “F/TAF”, 8 entries
  • “B/F/TAF (TOS)”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.